Imfinzi

Who we are

  • October 31, 2023
    Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
  • April 5, 2022
    A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
  • April 5, 2022
    Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens